The long-term objective of our investigations is to examine how, where and when the pharmacokinetics of organic nitrates may relate to their pharmacologic and therapeutic effects. The organic nitrates are used in a broad spectrum of cardiovascular diseases, and are still the first-line therapeutic agents against which the effectiveness of other vasodilators are judged. The organic nitrates also possess a number of unusual pharmacokinetic features, and they serve as useful model compounds for the study of other drugs which are rapidly cleared from the body. Our focus on the vascular pharmacokinetics of organic nitrates has proven to be a useful investigative approach in the understanding of nitrate action. In this proposal, our main goals are to utilize this approach in an examination of the implications of the mode of dosing (i.e., whether continuous or intermittent) on vascular nitrate activity and pharmacokinetics, and in an assessment of the usefulness of nitrate metabolites and thiol compounds in enhancing nitrate action. Through the studies proposed, we hope to achieve a better understanding of the pharmacokinetic determinants of nitrate action and to evolve a rational approach to the optimization of dosage regimens for these drugs.
Our specific aims are (i) to examine whether the systemic clearance of nitroglycerin is limited by the cardiac output, (ii) to investigate the pharmacokinetics of nitroglycerin in blood vessels of various morphologies as functions of dosage regimen and degree of nitrate tolerance, (iii) to study the role of nitrate metabolites in vascular tolerance, (iv) to examine whether metabolite interaction occurs during hepatic extraction of organic nitrates, and (v) to explore the potential of systemically administered thiol compounds for imporving nitrate therapy.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL022273-09
Application #
3336814
Study Section
Pharmacology A Study Section (PHRA)
Project Start
1978-04-01
Project End
1988-06-30
Budget Start
1986-07-01
Budget End
1987-06-30
Support Year
9
Fiscal Year
1986
Total Cost
Indirect Cost
Name
State University of New York at Buffalo
Department
Type
Schools of Pharmacy
DUNS #
038633251
City
Buffalo
State
NY
Country
United States
Zip Code
14260
Fung, Ho-Leung (2004) Biochemical mechanism of nitroglycerin action and tolerance: is this old mystery solved? Annu Rev Pharmacol Toxicol 44:67-85
Wang, Ellen Q; Balthasar, Joseph P; Fung, Ho-Leung (2004) Pharmacodynamics of in vivo nitroglycerin tolerance in normal conscious rats: effects of dose and dosing protocol. Pharm Res 21:114-20
Khanna, Ashish; Rossman, Jon; Caty, Michael G et al. (2003) Beneficial effects of intraluminal nitroglycerin in intestinal ischemia-reperfusion injury in rats. J Surg Res 114:15-24
Lee, Woo In; Fung, Ho Leung (2003) Mechanism-based partial inactivation of glutathione S-transferases by nitroglycerin: tyrosine nitration vs sulfhydryl oxidation. Nitric Oxide 8:103-10
Lee, Woo-In; Xu, Ye; Fung, Sun-Mi et al. (2003) eNOS-dependent vascular interaction between nitric oxide and calcitonin gene-related peptide in mice: gender selectivity and effects on blood aggregation. Regul Pept 110:115-22
Wang, Ellen Q; Lee, Woo-In; Brazeau, Daniel et al. (2002) cDNA microarray analysis of vascular gene expression after nitric oxide donor infusions in rats: implications for nitrate tolerance mechanisms. AAPS PharmSci 4:E10
Wang, Ellen Q; Fung, Ho-Leung (2002) Effects of obesity on the pharmacodynamics of nitroglycerin in conscious rats. AAPS PharmSci 4:E28
Maurer, T; Fung, H L (2000) Comparison of methods for analyzing kinetic data from mechanism-based enzyme inactivation: application to nitric oxide synthase. AAPS PharmSci 2:E8
Maurer, T S; Fung, H L (2000) Evaluation of nitric oxide synthase activity and inhibition kinetics by chemiluminescence. Nitric Oxide 4:372-8
Tseng, C M; Tabrizi-Fard, M A; Fung, H L (2000) Differential sensitivity among nitric oxide donors toward ODQ-mediated inhibition of vascular relaxation. J Pharmacol Exp Ther 292:737-42

Showing the most recent 10 out of 76 publications